Search clinical trials for: mFOLFOXIRI

Total 76 results

Azienda Ospedaliero, Universitaria Pisana

Completed

FOLFOXIRI as Primary Treatment for Locally Advanced Pancreatic Cancer (FLAP)

Pancreatic Carcinoma Stage III

Italy
First Affiliated Hospital of Zhejiang University
Zhejiang Cancer Hospital; First Affiliated Hospital of Wenzhou Medical University

Recruiting

A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC

Locally Advanced Rectal Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Advanced Colorectal Cancer
AIPING ZHOU

Completed

Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Fudan University

Recruiting

Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Colorectal Cancer | Liver Metastases

China
Catharina Ziekenhuis Eindhoven

Not yet recruiting

Induction Chemotherapy for Locally Advanced Rectal Cancer (MEND-IT)

Rectal Cancer

Netherlands
Kasr El Aini Hospital

Completed

Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma

Metastatic Colorectal Cancer

Egypt
Gruppo Oncologico del Nord-Ovest

Completed

FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer (TRIP)

Metastatic Colo-rectal Cancer

Italy
Sixth Affiliated Hospital, Sun Yat-sen University

Not yet recruiting

Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Rectal Cancer | Chemotherapy Effect
Fudan University

Recruiting

IV Ascorbic Acid in Peritoneal Metastatic Colorectal Cancer

Colorectal Cancer | Vitamin C | GLUT3

China
Gruppo Oncologico del Nord-Ovest

Completed

Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient (MACBETH)

Metastatic Colorectal Cancer

Italy
Peking University

Unknown

mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial

Advanced Esophageal Carcinoma

China
Sun Yat-sen University
Guangzhou Burning Rock Dx Co., Ltd.

Recruiting

MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer (MIRROR)

Colorectal Cancer

China
Sun Yat-sen University

Not yet recruiting

Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy

Colorectal Cancer
Stanford University

Active, not recruiting

Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer

Rectal Cancer

United States
Rutgers, The State University of New Jersey

Recruiting

sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

Gastro-Intestinal Cancer

United States
University of Utah
Pfizer

Completed

A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers

Advanced KRAS Positive Metastatic Colorectal Cancer

United States
Sun Yat-sen University

Recruiting

Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer (OPTICAL-2)

Colorectal Cancer

China
West China Hospital
GeneCast Biotechnology Co., Ltd.

Recruiting

ctDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial) (REVISE)

Colon Cancer

China
Hanoi Medical University

Completed

Research on the Treatment of Metastatic Colon Cancer Patients Treated by FOLFOXIRI

Colorectal Cancer

Vietnam
University of Utah

Terminated

Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer (IPOX-FOLFIRI)

Colorectal Cancer | Peritoneal Carcinoma | Appendiceal Cancer

United States
Sun Yat-sen University

Recruiting

Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers

Colon Cancer Stage II | Colon Cancer Stage III

China
Peking University

Unknown

mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus

Advanced Esophageal Carcinoma

China
First Affiliated Hospital of Zhejiang University

Unknown

Neoadjuvant mFOLFOXIRI Chemotherapy Alone for Extramural Vascular Invasion Positive Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Sun Yat-sen University

Recruiting

Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation

Rectal Cancer

China
AIO-Studien-gGmbH
Amgen; ClinAssess GmbH

Completed

FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) (VOLFI)

Metastatic Colorectal Cancer

Germany
Cancer Institute and Hospital, Chinese Academy...

Enrolling by invitation

Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Rectal Cancer

Gastrointestinal Neoplasms | Intestinal Neoplasms | Rectal Diseases | Rectal Neoplasms | Lymph Node Metastasis | Oxaliplatin | Cancer of Rectum and Anus

China
Chinese University of Hong Kong

Active, not recruiting

Colon Neoadjuvant FOLFOXIRI Study

Rectal Cancer

Hong Kong
Yonsei University

Recruiting

A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer

Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy | Unresectable Metastatic Right-sided Colon Cancer, Stage IV

Korea, Republic of
RenJi Hospital

Active, not recruiting

Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer

Rectal Cancer Stage III

China
Fudan University

Recruiting

mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Liver Metastases | Colorectal Carcinoma

China
Sun Yat-sen University

Completed

FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer (FOCULM)

Metastatic Colorectal Cancer

China
Sun Yat-sen University

Unknown

FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type (FORBES)

Metastatic Colorectal Cancer

China
Cho Ray Hospital
University of Medicine and Pharmacy at Ho Chi Minh City

Recruiting

Surgery Outcome Treated by Neo-adjuvant Combination of Oxaliplatin, Irinotecan, Folinic Acid and Fluorouracil (FOLFOXIRI) Regimen in Synchronous Liver Limited Metastasis Colorectal Cancer

Synchronous Neoplasm | Liver Metastasis Colon Cancer

Vietnam
Hospital Universitari de Bellvitge
Instituto de Salud Carlos III

Terminated

Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases (CCRe-IV)

Colonic Cancer | Unresectable Metastasis Originating in Colonic Cancer

Spain
Azienda Ospedaliero, Universitaria Pisana

Completed

First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Italy
National Center for Tumor Diseases, Heidelberg
Pfizer; Roche Pharma AG

Terminated

Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy (APRIORI)

Colorectal Carcinoma

Germany
Sun Yat-sen University

Completed

Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer (FORTUNE)

Rectal Cancer

China
Spanish Cooperative Group for the Treatment of...
Roche Pharma AG

Completed

Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells (VISNU-1)

Metastatic Colorectal Cancer

Spain
RenJi Hospital

Unknown

Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Rectal Cancer

China
Fudan University

Recruiting

FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

Liver Metastasis Colon Cancer

China
Azienda Ospedaliero, Universitaria Pisana

Completed

Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer (TRUST)

Rectal Cancer

Italy
Hasselt University
Ziekenhuis Oost-Limburg

Terminated

Spot Urinary Analysis to Assess Loop Diuretic Efficiency in Stable Heart Failure (DIPSTICK)

Heart Failure

Belgium
Azienda Ospedaliero, Universitaria Pisana

Unknown

Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer (GIP-2)

Pancreatic Cancer

Italy
Fudan University

Recruiting

Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer (RCNAC)

Rectal Cancer

China
Khon Kaen University

Recruiting

Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma

Cholangiocarcinoma

Thailand
PregLem SA

Completed

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII)

Uterine Fibroids

Belgium, Poland, Austria, Spain
AMAG Pharmaceuticals, Inc.

Terminated

Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women

United States
Centre Hospitalier Universitaire Dijon
National Cancer Institute, France

Recruiting

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary (FOLFIRINEC)

Neuroendocrine Carcinoma

France
Medical University of Vienna

Unknown

Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer (CARCINOSIS)

Colorectal Cancer | Peritoneal Metastasis

Austria

3

Subscribe